Business Wire

WA-VOUCHED

13.4.2021 12:02:09 CEST | Business Wire | Press release

Share
Vouched and Verisart Partner to Provide Peace of Mind for NFT Artists, Investors

Power to the Beeple, and to every other artist, collector, and investor working to expand the boundaries of fine art by bringing works tied to nonfungible tokens (NFTs) to the mainstream.

Vouched and Verisart today announced an industry-first partnership to apply Vouched’s unique digital identity verification technology to Verisart’s first-of-its-kind blockchain certification platform for digital artists and collectors. The partnership is a significant step forward for the NFT art industry, which has recently seen spikes in interest after a piece created by artist Beeple sold for $69.3 million, a new record for purely digital work.

“The rise of NFTs demonstrates that virtually everything in our known history can be adapted to a digital future, from healthcare to banking to real estate, and now fine art,” said John Baird, Co-Founder, and CEO of Vouched. “Identity verification is absolutely foundational to every element of this ongoing digital revolution. We are excited to work with Verisart to bring Vouched’s unmatched AI technology to the world of NFT art, helping to unleash creativity for artists and enable more confident investing for collectors.”

Vouched’s identity verification platform will be used as part of Verisart’s new patent-pending global standard for digital art certification, enabling creators, collectors, and dealers to easily create digital certificates registered on the blockchain.

“While there may be a lot of hype around the NFT art market right now, it highlights an important advancement that is here to stay and will continue to reshape how we create, authenticate and value those creations moving forward,” said Robert Norton, CEO of Verisart. “Verisart is pioneering the capability to apply blockchain to certification in the art and collectibles market. We support creativity by facilitating trusted transactions and empowering artists to establish their careers and legacies, regardless of what their works sell for.”

Starting immediately, artists can create secure certificates of authenticity for their NFTs on Verisart using Vouched’s platform by using their ID and Vouched’s facial recognition tools to ensure they are who they say they are. The same process is being utilized for collectors on Verisart to verify purchaser identity, creating an extra layer of security for both the artist and the buyer.

About Vouched

Vouched is proprietary artificial intelligence and computer vision that powers end-to-end visual identity verification and fraud detection online in real-time. An expert on more than 450 government-issued identity documents, including driver’s licenses, passports, and permanent resident cards, in 50+ countries, Vouched helps banks, gig and sharing companies, and hospital and healthcare providers verify and onboard users to provide access to life’s most critical services instantly.

For more information on Vouched, visit www.vouched.id , or contact Vouched communications at 1-800-674-8798 or press@vouched.id .

About Verisart

Verisart is an award-winning certification service enabling artists, galleries, and collectors to create certificates of authenticity securely registered on the blockchain. Founded in 2015 as the first company to apply blockchain to certification in the art and collectibles market, Verisart has pioneered a new patent-pending global standard for certification. Over 20,000 artworks have been certified on the platform by more than 5000 artists including Shepard Fairey, Ai Weiwei, Jules De Balincourt, Penny Slinger, and Derek Boshier.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye